Lu sur https://www.ncbi.nlm.nih.gov/pubmed/28045063
Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum
Profile of upregulated inflammatory proteins in sera of Myasthenia Gravis patients.
Molin CJ1, Westerberg E1, Punga AR1.
Sci Rep. 2017 Jan 3;7:39716. doi: 10.1038/srep39716.
This study describes specific patterns of elevated inflammatory proteins in clinical subtypes of myasthenia gravis (MG) patients. MG is a chronic, autoimmune neuromuscular disease with antibodies most commonly targeting the acetylcholine receptors (AChRab), which causes fluctuating skeletal muscle fatigue.
MG pathophysiology includes a strong component of inflammation, and a large proportion of patients with early onset MG additionally present thymus hyperplasia.
Due to the fluctuating nature and heterogeneity of the disease, there is a great need for objective biomarkers as well as novel potential inflammatory targets.
We examined the sera of 45 MG patients (40 AChRab seropositive and 5 AChRab seronegative), investigating 92 proteins associated with inflammation.
Eleven of the analysed proteins were significantly elevated compared to healthy controls, out of which the three most significant were:
matrix metalloproteinase 10 (MMP-10; p = 0.0004), transforming growth factor alpha (TGF-α; p = 0.0017) and extracellular newly identified receptor for advanced glycation end-products binding protein (EN-RAGE) (also known as protein S100-A12; p = 0.0054). Further, levels of MMP-10, C-X-C motif ligand 1 (CXCL1) and brain derived neurotrophic factor (BDNF) differed between early and late onset MG.
These novel targets provide valuable additional insight into the systemic inflammatory response in MG.